{"ticker": {"uuid": "d4d96f73-d1a8-45ca-888c-710dd3765e65", "symbol": "BIO-B", "name": "Bio-Rad Laboratories Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxORk9ENlh5SlJsMWUxNEQxVlpSRENmeGxhU0hUdE02bERwWWZRSEZTeWRKZ1BuREhJOUppdTVnV0VjZ0tibGRpa0lzR1h4OXJNM1ZQdjA1YXVJbkZnd3N6U2xGX3hjaFVESWp5RWpQN2tOVG96ZnpCMUhZd0hha3NMZ3Z0Z1pEbHNpM2ZVSEFQQUVIQjFVTGNUUmlFNXhBQ3pmWWl3ODV5V29FeVdIVmNUMnJfN2xKTm9hQ3RGSTFqeEhIVGtrU3c?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-17T17:35:02+00:00", "published_display": "17 Jul 2026 17:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQNzZYRWxBSV90WVhtR0ljY3BvSEM3WmFRRUFyRlRCdFFOTF8xblF4YTJZN3FWNzRjS0pjV29VZXR4akxObWREbmJHWTFuZUdpYmEzOEZ2NThodF9DaWVvX3hUTmxtZjNlQl85UEFMYnh4VnVDUUMtTllFZmFqRnhDaXlERHJNdEtJZXlUMWpDVzNsS1ZNNlVfc2c5Mk0xZEItdmZhT1BITDFMT3JQQWdqRjladzhnTm1ycDl0cEZ3UFQzMlR2V1d4MWtQWEF0UEtEVUVMQW9hN1JkQnZXOTNvUE91YmlBR0syV1FtbC02NE1kNFZuaVFB?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-12T02:45:02+00:00", "published_display": "12 Jul 2026 02:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories outlines its diagnostics and life science strategy for long-term growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQcU43QU5VN2paMjlKMG1MenptUVFzQ09zcG5WakRIV2VndlZ6NXNCZnAxZjJhY1FCT2ExX1ktRzRXcWVjSk50WGtReFJCMFRtN3JTdjJseXJSQWIweURHbXkzUEtNdDdOclZCbTYzOFd1WGZoZ08wdThaMks1T3MyTGJvNkdzYzB0LUJpbmF2Q1V0UHo5QlBVZlZiZ1dpUFktMzkwV09OdXhldTlIeGlsa1hDeTA3bDBOdjNySXR5Q1lpdV9OcHYtREFB?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Bio-Rad Laboratories (BIO)'s Activist Pressure and Sartorius Stake Review Means For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BUWA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Bio-Rad Laboratories, Inc. Class A (BUWA) stock, including price targets from analysts and historical performance. It details the company's financials, earnings reports, revenue, net income, and current market capitalization. The article also ", "url": "https://www.tradingview.com/symbols/GETTEX-BUWA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:50", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BIO", "summary": "This article provides comprehensive financial data, news, and analyst ratings for Bio-Rad Laboratories Inc. (BIO). It includes key metrics such as stock price, market capitalization, P/E ratio, and recent insider transactions. The news section highlights recent events like activi", "url": "https://finviz.com/stock?t=BIO", "source_name": "Finviz", "published_at": "2026-05-28T19:39:07", "published_display": "28 May 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE l", "summary": "Bio-Rad Laboratories shares are trading firmly above USD 300 on the NYSE, attracting investor attention due to an activist stake by Elliott Investment Management and recent price target updates. The company, a mid-cap life-science tools provider, has seen over 30% gains in the la", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/bio-rad-laboratories-stock-us09062x1037-sector-focus-as-elliott-stake/69433989", "source_name": "Ad Hoc News", "published_at": "2026-05-28T14:40:59", "published_display": "28 May 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad (NYSE: BIO) EVP Engelhardt sells 550 A shares in open market", "summary": "Eva Anette Engelhardt, EVP and President of the Clinical Diagnostics Group at Bio-Rad Laboratories (NYSE: BIO), reported an open-market sale of 550 shares of Bio-Rad A Common Stock on May 11, 2026, at a price of $246.54 per share. Following this transaction, Engelhardt directly h", "url": "https://www.stocktitan.net/sec-filings/BIO/form-4-bio-rad-laboratories-inc-insider-trading-activity-77124c1f6fc2.html", "source_name": "Stock Titan", "published_at": "2026-05-27T20:09:44", "published_display": "27 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Elliott\u2019s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNc3UyUG83Z2lGREpheWdpOHN6NUNlemt2WldhTzgyaVBTcDZ6ZGJ4Zi1Td3VQQnZzU3ZpR1JyYS1JaXJqRW4yV1l1VUt5MDRYNlBPeDNUSGZsVFQ5a0MzM2RsZ1NOVmRxY2hsTW54aWRrUmdlSnhLSlZfam1SSHFyZ3VWQ1BYaTd5ZUxvSVNVQklfYl9xNlh4WmRWLU9DS2FuMHJ4TUczeDM5dEZhS052Rw?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Bio-Rad Laboratories (BIO) After Its Recent 16% Weekly Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bio-Rad Laboratories (BIO) Stock Soars 13% on Elliott Management Investment News", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPSEFXcy1NZDJVNm9UWE0tRmx6TTlSdmJxb3g5Y2N0NXFiNDFxYWxWZ01MYzk5eG1aRHBhX1dJalZKU3pzTEQwa014S0ZPNHFMZzJ3TzMxNmlIMW13RHYwV2VaS0JJMW9aeFJGSlpRakg0M2FnczZZMWhNcUFWWEVHOVQ5Y3E3ZWpIeUM4WkJGY0hSNTdlRVY1Q1pqa2gtcC1xZW1BeThpeFB1ZUhkUnpJdlJtaFlXZUpqUHJTZkxGYmJoR3d2cnc?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley files Rule 144 notice to sell 550 BIO shares (NYSE: BIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOZFpyTVpSaDR2Z0hINE5uRUxHX29BN29aRmNWT2dYYXNGQ0h4MXZjUUViNUlDVm12ZEo5STZHQklyYl8xZjFWTkhKaDV3WmFIdlhQN3dMSlV0NzMzWU1vOHlRSDl2dGxYcUZWWHU1cV9MTThNZFdpN1dnZGc3Mi1yYlpUeW1wdFV4OGtJVWd4R1BZUFpONVpVNzNpQnpBUkZtNmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out", "summary": "Ariel Investments' Ariel Focus Fund re-added Bio-Rad Laboratories (BIO) to its portfolio, highlighting the company's strong financial profile, diversified market footprint, and market leadership in life science research and clinical diagnostics. The fund emphasized Bio-Rad's risi", "url": "https://finance.yahoo.com/markets/stocks/articles/ariel-investments-added-bio-rad-161444298.html", "source_name": "Market source", "published_at": "2026-05-05T17:09:12", "published_display": "05 May 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (NYSE:BIO) - Stock Analysis", "summary": "This article provides a stock analysis of Bio-Rad Laboratories (NYSE:BIO), highlighting its valuation, future growth, past performance, financial health, and recent news. The company, which develops and distributes life science research and clinical diagnostic products, is curren", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories", "source_name": "Simply Wall Street", "published_at": "2026-05-04T09:40:20", "published_display": "04 May 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio Rad Laboratories (BIO) EPS Loss Revives Concerns Over Volatile Profit Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (NYSE:BIO.B) Posts Earnings Results", "summary": "Bio-Rad Laboratories (NYSE:BIO.B) announced its quarterly earnings, reporting an EPS of $1.89. The company demonstrated strong profitability with a net margin of 29.42% and a return on equity of 3.86%. Shares traded up by $22.45 to $299.45 following the report, with the company m", "url": "https://www.marketbeat.com/instant-alerts/bio-rad-laboratories-nysebiob-posts-earnings-results-2026-04-30/", "source_name": "MarketBeat", "published_at": "2026-04-30T21:39:34", "published_display": "30 Apr 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad (NYSE: BIO) posts Q1 loss and trims 2026 guidance", "summary": "Bio-Rad Laboratories reported a Q1 2026 net sales increase of 1.1% year-over-year to $592.1 million, but a 4.2% currency-neutral decrease, resulting in a large GAAP net loss of $527.1 million primarily due to an investment fair value change. The company also lowered its full-year", "url": "https://www.stocktitan.net/sec-filings/BIO/8-k-bio-rad-laboratories-inc-reports-material-event-84ad2c3fc6a1.html", "source_name": "Stock Titan", "published_at": "2026-04-30T20:39:34", "published_display": "30 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Huge Sartorius loss drives Bio-Rad (NYSE: BIO) Q1 2026 net loss", "summary": "Bio-Rad Laboratories reported a net loss of $527.1 million in Q1 2026, primarily due to a $738.2 million fair-value loss from equity securities and a loan receivable, including a significant $727.7 million holding loss on its investment in Sartorius AG. Despite this, net sales sl", "url": "https://www.stocktitan.net/sec-filings/BIO/10-q-bio-rad-laboratories-inc-quarterly-earnings-report-f49d8af29bd4.html", "source_name": "Stock Titan", "published_at": "2026-04-30T20:38:50", "published_display": "30 Apr 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad earnings on deck: Can margins recover after rough 2025?", "summary": "Bio-Rad Laboratories is set to report its first-quarter earnings, with investors keenly watching for signs of margin recovery after a challenging 2025 where performance fell below expectations. Analysts anticipate earnings of $2.01 per share on $591.28 million in revenue. Key fac", "url": "https://au.investing.com/news/earnings/biorad-earnings-on-deck-can-margins-recover-after-rough-2025-93CH-4397325", "source_name": "Investing.com Australia", "published_at": "2026-04-30T14:38:50", "published_display": "30 Apr 2026 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bio-Rad will release Q1 results after market close on April 30", "summary": "Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced it will report its first-quarter 2026 financial results on Thursday, April 30, 2026, after the market closes. Management will host a conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) to discuss the results, w", "url": "https://www.stocktitan.net/news/BIO/bio-rad-to-report-first-quarter-2026-financial-results-on-thursday-r2s8rlzcf1pp.html", "source_name": "Stock Titan", "published_at": "2026-04-16T15:09:20", "published_display": "16 Apr 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vanguard disaggregates holdings; Bio\u2011Rad Labs (NYSE: BIO) shows 0 shares", "summary": "The Vanguard Group filed an amended Schedule 13G/A for Bio-Rad Laboratories Inc. (NYSE: BIO), reporting beneficial ownership of 0 shares (0%) due to an internal realignment on January 12, 2026. This disaggregation of holdings means certain Vanguard subsidiaries will now report th", "url": "https://www.stocktitan.net/sec-filings/BIO/schedule-13g-a-bio-rad-laboratories-inc-amended-passive-investment-di-e516707415ee.html", "source_name": "Stock Titan", "published_at": "2026-03-26T20:38:51", "published_display": "26 Mar 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Disappointing Results Hurt Bio-Rad Laboratories (BIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNTFZxX09fWUR1Nk91TVUtb0MxSHJCNWpsREMzQnh4SkNEZHZDcHFhZXpocWZGQlUzLU96WWdRQ0Y4a1NjUzk3ckZiV1pfTkM1X0xlSE9jaU9JUk5vUEN2aXprVjJsMHEwM29hZFJmblg5RHNRMjJfU3BSRXBXczRPZkZzNTFSUmVZd3BKbndna2JuVzVTOVF4Q2htdE13ZU1B?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hound Partners LLC Has $29.15 Million Stake in Bio-Rad Laboratories, Inc. $BIO", "summary": "Hound Partners LLC significantly reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 42.9% in the third quarter, now holding 103,963 shares valued at $29.15 million. This represents about 3.7% of Hound's portfolio. Despite mixed analyst sentiment with a \"Hold\" rating an", "url": "https://www.marketbeat.com/instant-alerts/filing-hound-partners-llc-has-2915-million-stake-in-bio-rad-laboratories-inc-bio-2026-03-16/", "source_name": "MarketBeat", "published_at": "2026-03-17T07:10:14", "published_display": "17 Mar 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bio-Rad Laboratories, Inc. $BIO Shares Purchased by Natixis Advisors LLC", "summary": "Natixis Advisors LLC significantly increased its stake in Bio-Rad Laboratories (NYSE:BIO) during Q3, purchasing an additional 26,119 shares, bringing their total to 65,069 shares valued at $18.25 million. This move is part of a broader trend of institutional investors modifying t", "url": "https://www.marketbeat.com/instant-alerts/filing-bio-rad-laboratories-inc-bio-shares-purchased-by-natixis-advisors-llc-2026-03-12/", "source_name": "MarketBeat", "published_at": "2026-03-12T18:53:00", "published_display": "12 Mar 2026 18:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capital Research Global Investors Makes New Investment in Bio-Rad Laboratories, Inc. $BIO", "summary": "Capital Research Global Investors has made a significant new investment in Bio-Rad Laboratories, purchasing 418,355 shares valued at approximately $117.3 million, representing about 1.55% ownership. This move comes as Bio-Rad reported Q4 EPS of $2.51, slightly missing estimates, ", "url": "https://www.marketbeat.com/instant-alerts/filing-capital-research-global-investors-makes-new-investment-in-bio-rad-laboratories-inc-bio-2026-03-12/", "source_name": "MarketBeat", "published_at": "2026-03-12T13:09:26", "published_display": "12 Mar 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10,425 Shares in Bio-Rad Laboratories, Inc. $BIO Purchased by Magnetar Financial LLC", "summary": "Magnetar Financial LLC recently acquired 10,425 shares of Bio-Rad Laboratories (NYSE:BIO) valued at approximately $2.923 million, contributing to institutional investors owning about 65.24% of the stock. Bio-Rad Laboratories reported mixed financial results, missing EPS estimates", "url": "https://www.marketbeat.com/instant-alerts/filing-10425-shares-in-bio-rad-laboratories-inc-bio-purchased-by-magnetar-financial-llc-2026-03-12/", "source_name": "MarketBeat", "published_at": "2026-03-12T10:52:26", "published_display": "12 Mar 2026 10:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Perbak Capital Partners LLP Purchases 5,423 Shares of Bio-Rad Laboratories, Inc. $BIO", "summary": "Perbak Capital Partners LLP significantly increased its stake in Bio-Rad Laboratories (NYSE: BIO) by 171.7% in the third quarter of 2026, acquiring 5,423 additional shares. The firm now holds 8,582 shares valued at $2.406 million, making it a substantial holding within their port", "url": "https://www.marketbeat.com/instant-alerts/filing-perbak-capital-partners-llp-purchases-5423-shares-of-bio-rad-laboratories-inc-bio-2026-03-14/", "source_name": "MarketBeat", "published_at": "2026-03-12T10:10:52", "published_display": "12 Mar 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TD Asset Management Inc Purchases 7,386 Shares of Bio-Rad Laboratories, Inc. $BIO", "summary": "TD Asset Management Inc. significantly increased its stake in Bio-Rad Laboratories (NYSE:BIO) by 461.0% in the third quarter, acquiring an additional 7,386 shares to hold a total of 8,988 shares valued at approximately $2.52 million. Despite this increased institutional interest,", "url": "https://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-purchases-7386-shares-of-bio-rad-laboratories-inc-bio-2026-03-05/", "source_name": "MarketBeat", "published_at": "2026-03-05T15:52:44", "published_display": "05 Mar 2026 15:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roubaix Capital LLC Buys Shares of 8,112 Bio-Rad Laboratories, Inc. $BIO", "summary": "Roubaix Capital LLC initiated a new position in Bio-Rad Laboratories (NYSE:BIO), acquiring 8,112 shares valued at approximately $2.275 million during the third quarter. The company reported slightly lower-than-expected quarterly earnings and revenue, with EPS of $2.51 against an ", "url": "https://www.marketbeat.com/instant-alerts/filing-roubaix-capital-llc-buys-shares-of-8112-bio-rad-laboratories-inc-bio-2026-03-03/", "source_name": "MarketBeat", "published_at": "2026-03-03T14:52:41", "published_display": "03 Mar 2026 14:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CenterBook Partners LP Has $2.56 Million Holdings in Bio-Rad Laboratories, Inc. $BIO", "summary": "CenterBook Partners LP reduced its stake in Bio-Rad Laboratories, Inc. by 36.4% in the third quarter, holding 9,129 shares valued at $2.56 million. Despite this, other institutions like Royal Bank of Canada and Goldman Sachs increased their positions, with institutional investors", "url": "https://www.marketbeat.com/instant-alerts/filing-centerbook-partners-lp-has-256-million-holdings-in-bio-rad-laboratories-inc-bio-2026-02-20/", "source_name": "MarketBeat", "published_at": "2026-02-24T16:52:53", "published_display": "24 Feb 2026 16:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sartorius 2025 results summarized in Bio-Rad (NYSE: BIO) update", "summary": "Bio-Rad Laboratories, Inc. (NYSE: BIO) has provided an update on its investment in Sartorius AG, sharing Sartorius's full-year 2025 financial figures which were disclosed on February 16, 2026. The update, filed as a Form 8-K, details Sartorius\u2019 sales revenue, gross profit, EBIT, ", "url": "https://www.stocktitan.net/sec-filings/BIO/8-k-bio-rad-laboratories-inc-reports-material-event-9de18110da65.html", "source_name": "Stock Titan", "published_at": "2026-02-23T13:52:01", "published_display": "23 Feb 2026 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(BIO) Movement Within Algorithmic Entry Frameworks", "summary": "This article provides an algorithmic analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details three trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014along with multi-timef", "url": "https://news.stocktradersdaily.com/news_release/21/BIO_Movement_Within_Algorithmic_Entry_Frameworks_022326123601_1771868161.html", "source_name": "Stock Traders Daily", "published_at": "2026-02-23T12:36:00", "published_display": "23 Feb 2026 12:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving Average - Time to Sell?", "summary": "Bio-Rad Laboratories (NYSE:BIO.B) shares have fallen below their 200-day moving average, trading at $261.83, which is below the $289.87 average, signaling a potential bearish technical trend. Despite this short-term weakness, the company's fundamentals remain strong, with robust ", "url": "https://www.marketbeat.com/instant-alerts/bio-rad-laboratories-nysebiob-shares-pass-below-200-day-moving-average-time-to-sell-2026-02-21/", "source_name": "MarketBeat", "published_at": "2026-02-21T12:51:52", "published_display": "21 Feb 2026 12:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics", "summary": "Bio-Rad Laboratories (BIO) recently informed investors about selected 2025 financial metrics from its strategic investment in Sartorius AG. Sartorius reported \u20ac3.54 billion in sales revenue and \u20ac542.6 million in EBIT for 2025, providing transparency on the financial health of thi", "url": "https://www.tipranks.com/news/company-announcements/bio-rad-updates-investors-on-sartorius-strategic-investment-metrics", "source_name": "TipRanks", "published_at": "2026-02-20T18:51:32", "published_display": "20 Feb 2026 18:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio Rad Laboratories Q3 Loss Of US$12.70 EPS Tests Recovery Narrative For BIO Stock", "summary": "Bio-Rad Laboratories (BIO) reported a Q3 FY 2025 basic EPS loss of US$12.70 and US$653 million in revenue, presenting a mixed picture against its volatile financial history. The company's trailing 12-month net loss is US$675.9 million, with analysts forecasting a return to profit", "url": "https://www.sahmcapital.com/news/content/bio-rad-laboratories-q3-loss-of-us1270-eps-tests-recovery-narrative-for-bio-stock-2026-02-14", "source_name": "Sahm", "published_at": "2026-02-16T13:52:01", "published_display": "16 Feb 2026 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPSTYxMFhyN2MtOVEyWWdSd1NjYzk5bHFxclJNVmlCLUdpektDWDE5THNmM3hXRXI3cDZ0bXhCZ3l5TnczbGNuSjhSdkx5cTV6ZE1oQlBsa01LLVJycS1feGIyUmxQRHNwV1gtLU9WMngwRjZRTURBRXE1YnJ4ZGtXZkRIZms3SXM?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (NYSE:BIO.B) Posts Quarterly Earnings Results", "summary": "Bio-Rad Laboratories (NYSE:BIO.B) recently announced its quarterly earnings, reporting $2.51 EPS. Despite a negative net margin of 26.43%, the company achieved a positive return on equity of 4.19%. Shares remained flat at $295.05 on minimal trading volume, indicating strong liqui", "url": "https://www.marketbeat.com/instant-alerts/bio-rad-laboratories-nysebiob-posts-quarterly-earnings-results-2026-02-12/", "source_name": "MarketBeat", "published_at": "2026-02-13T00:27:54", "published_display": "13 Feb 2026 00:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQQ0stWDJjdVBBNHFUcWFFSkw2S0FfV0IzWXRtalJ4N192a0RvQl9UOUlVSjJrQTRQUWNZUUc4bXdMX0VxSUJ1TDUyakhEMFpUOFNHaTNPbUVGblhDVl9pYzktQlZyMi0yYURYa1JsdGZzREQ5YXdOWE1HZEhYLTBlYw?oc=5", "source_name": "Market source", "published_at": "2025-03-07T08:00:00+00:00", "published_display": "07 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories: This Undervalued Stock Offers Investors a Rare Combination", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxORVczUEktaG9PZ1dkMjMxWTk1TDZlUVFCX0dvbFZ6eEJTd2VXVmlFZWZZNXI0WUJ0UUFtMm4xanpSOTc0YS1VRHhBLUJ5dlBTRUxQMTNiTEkwQ2gwS1NnU3VwX1EyUVFEdVFTMmxBd0I0bDdkYTFLMTUxQzdxSFJOeG9VbXhMQTJqdmZrZ3dDN3ROMTJTaWc?oc=5", "source_name": "Morningstar", "published_at": "2024-11-11T08:00:00+00:00", "published_display": "11 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxORk9ENlh5SlJsMWUxNEQxVlpSRENmeGxhU0hUdE02bERwWWZRSEZTeWRKZ1BuREhJOUppdTVnV0VjZ0tibGRpa0lzR1h4OXJNM1ZQdjA1YXVJbkZnd3N6U2xGX3hjaFVESWp5RWpQN2tOVG96ZnpCMUhZd0hha3NMZ3Z0Z1pEbHNpM2ZVSEFQQUVIQjFVTGNUUmlFNXhBQ3pmWWl3ODV5V29FeVdIVmNUMnJfN2xKTm9hQ3RGSTFqeEhIVGtrU3c?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-17T17:35:02+00:00", "published_display": "17 Jul 2026 17:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQNzZYRWxBSV90WVhtR0ljY3BvSEM3WmFRRUFyRlRCdFFOTF8xblF4YTJZN3FWNzRjS0pjV29VZXR4akxObWREbmJHWTFuZUdpYmEzOEZ2NThodF9DaWVvX3hUTmxtZjNlQl85UEFMYnh4VnVDUUMtTllFZmFqRnhDaXlERHJNdEtJZXlUMWpDVzNsS1ZNNlVfc2c5Mk0xZEItdmZhT1BITDFMT3JQQWdqRjladzhnTm1ycDl0cEZ3UFQzMlR2V1d4MWtQWEF0UEtEVUVMQW9hN1JkQnZXOTNvUE91YmlBR0syV1FtbC02NE1kNFZuaVFB?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-12T02:45:02+00:00", "published_display": "12 Jul 2026 02:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories outlines its diagnostics and life science strategy for long-term growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQcU43QU5VN2paMjlKMG1MenptUVFzQ09zcG5WakRIV2VndlZ6NXNCZnAxZjJhY1FCT2ExX1ktRzRXcWVjSk50WGtReFJCMFRtN3JTdjJseXJSQWIweURHbXkzUEtNdDdOclZCbTYzOFd1WGZoZ08wdThaMks1T3MyTGJvNkdzYzB0LUJpbmF2Q1V0UHo5QlBVZlZiZ1dpUFktMzkwV09OdXhldTlIeGlsa1hDeTA3bDBOdjNySXR5Q1lpdV9OcHYtREFB?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Bio-Rad Laboratories (BIO)'s Activist Pressure and Sartorius Stake Review Means For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BUWA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Bio-Rad Laboratories, Inc. Class A (BUWA) stock, including price targets from analysts and historical performance. It details the company's financials, earnings reports, revenue, net income, and current market capitalization. The article also ", "url": "https://www.tradingview.com/symbols/GETTEX-BUWA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:50", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIO", "summary": "This article provides comprehensive financial data, news, and analyst ratings for Bio-Rad Laboratories Inc. (BIO). It includes key metrics such as stock price, market capitalization, P/E ratio, and recent insider transactions. The news section highlights recent events like activi", "url": "https://finviz.com/stock?t=BIO", "source_name": "Finviz", "published_at": "2026-05-28T19:39:07", "published_display": "28 May 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE l", "summary": "Bio-Rad Laboratories shares are trading firmly above USD 300 on the NYSE, attracting investor attention due to an activist stake by Elliott Investment Management and recent price target updates. The company, a mid-cap life-science tools provider, has seen over 30% gains in the la", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/bio-rad-laboratories-stock-us09062x1037-sector-focus-as-elliott-stake/69433989", "source_name": "Ad Hoc News", "published_at": "2026-05-28T14:40:59", "published_display": "28 May 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad (NYSE: BIO) EVP Engelhardt sells 550 A shares in open market", "summary": "Eva Anette Engelhardt, EVP and President of the Clinical Diagnostics Group at Bio-Rad Laboratories (NYSE: BIO), reported an open-market sale of 550 shares of Bio-Rad A Common Stock on May 11, 2026, at a price of $246.54 per share. Following this transaction, Engelhardt directly h", "url": "https://www.stocktitan.net/sec-filings/BIO/form-4-bio-rad-laboratories-inc-insider-trading-activity-77124c1f6fc2.html", "source_name": "Stock Titan", "published_at": "2026-05-27T20:09:44", "published_display": "27 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Elliott\u2019s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNc3UyUG83Z2lGREpheWdpOHN6NUNlemt2WldhTzgyaVBTcDZ6ZGJ4Zi1Td3VQQnZzU3ZpR1JyYS1JaXJqRW4yV1l1VUt5MDRYNlBPeDNUSGZsVFQ5a0MzM2RsZ1NOVmRxY2hsTW54aWRrUmdlSnhLSlZfam1SSHFyZ3VWQ1BYaTd5ZUxvSVNVQklfYl9xNlh4WmRWLU9DS2FuMHJ4TUczeDM5dEZhS052Rw?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Bio-Rad Laboratories (BIO) After Its Recent 16% Weekly Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (BIO) Stock Soars 13% on Elliott Management Investment News", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPSEFXcy1NZDJVNm9UWE0tRmx6TTlSdmJxb3g5Y2N0NXFiNDFxYWxWZ01MYzk5eG1aRHBhX1dJalZKU3pzTEQwa014S0ZPNHFMZzJ3TzMxNmlIMW13RHYwV2VaS0JJMW9aeFJGSlpRakg0M2FnczZZMWhNcUFWWEVHOVQ5Y3E3ZWpIeUM4WkJGY0hSNTdlRVY1Q1pqa2gtcC1xZW1BeThpeFB1ZUhkUnpJdlJtaFlXZUpqUHJTZkxGYmJoR3d2cnc?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley files Rule 144 notice to sell 550 BIO shares (NYSE: BIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOZFpyTVpSaDR2Z0hINE5uRUxHX29BN29aRmNWT2dYYXNGQ0h4MXZjUUViNUlDVm12ZEo5STZHQklyYl8xZjFWTkhKaDV3WmFIdlhQN3dMSlV0NzMzWU1vOHlRSDl2dGxYcUZWWHU1cV9MTThNZFdpN1dnZGc3Mi1yYlpUeW1wdFV4OGtJVWd4R1BZUFpONVpVNzNpQnpBUkZtNmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out", "summary": "Ariel Investments' Ariel Focus Fund re-added Bio-Rad Laboratories (BIO) to its portfolio, highlighting the company's strong financial profile, diversified market footprint, and market leadership in life science research and clinical diagnostics. The fund emphasized Bio-Rad's risi", "url": "https://finance.yahoo.com/markets/stocks/articles/ariel-investments-added-bio-rad-161444298.html", "source_name": "Market source", "published_at": "2026-05-05T17:09:12", "published_display": "05 May 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (NYSE:BIO) - Stock Analysis", "summary": "This article provides a stock analysis of Bio-Rad Laboratories (NYSE:BIO), highlighting its valuation, future growth, past performance, financial health, and recent news. The company, which develops and distributes life science research and clinical diagnostic products, is curren", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories", "source_name": "Simply Wall Street", "published_at": "2026-05-04T09:40:20", "published_display": "04 May 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio Rad Laboratories (BIO) EPS Loss Revives Concerns Over Volatile Profit Narratives", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQZnFoQUt4S2lkSTNGOW05dnJnelJuTHZvdnhZU0d0VEh0dGlZZFhiTGZnYW5CbXpPQ1FVRUVsaWJUeFRkYlR5eVkzR19iOHE3NHUyWDdveXNvSllsa3RRVFJEOThvamNZSFJHU2JDMk1WT1FMYUo0czQtX0ZKUF9HMWhqOXM5azZRU1J6aWtQN3lZRm16T21vY0RYdy1ZLXNrQWJBSTFCWHRydi1yREVPZF9ndDJ4N2hTQ0dMelpBNmN4T3VEZkY0TklKWFhIS3JwakJkallVTFlIeVE2MmszeHdsY3ZpZ9IB6wFBVV95cUxNY0R0V2ZMT2JkV2VuV09iWHZDQkdCT2o4OVAzTS1ITzRkU2RYSzE3YV85cVZKT3NpVGRNUF9qR1ZzQ1lTc1E0QXhZdUU0NlhaaEFXblVrenNXU1l5SFZrbDZwYzJHVkxlR3ZmTzYzZzBvbGpMZGxQV2NTTkZMMkhfNms1Uy0zaVdqcGwxT09hYXlPWld3RXNtaDlpVk9XckdVbTRmR0tpVzZKdTBWcXVxU2NGUmNjRHNKWldwQkJiUzlzdm03WVVnSGlWa1E4ZnlqUG1XM2ctZTBTc0xKTHlTXzF5cnVvcXhXX0Jn?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (NYSE:BIO.B) Posts Earnings Results", "summary": "Bio-Rad Laboratories (NYSE:BIO.B) announced its quarterly earnings, reporting an EPS of $1.89. The company demonstrated strong profitability with a net margin of 29.42% and a return on equity of 3.86%. Shares traded up by $22.45 to $299.45 following the report, with the company m", "url": "https://www.marketbeat.com/instant-alerts/bio-rad-laboratories-nysebiob-posts-earnings-results-2026-04-30/", "source_name": "MarketBeat", "published_at": "2026-04-30T21:39:34", "published_display": "30 Apr 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad (NYSE: BIO) posts Q1 loss and trims 2026 guidance", "summary": "Bio-Rad Laboratories reported a Q1 2026 net sales increase of 1.1% year-over-year to $592.1 million, but a 4.2% currency-neutral decrease, resulting in a large GAAP net loss of $527.1 million primarily due to an investment fair value change. The company also lowered its full-year", "url": "https://www.stocktitan.net/sec-filings/BIO/8-k-bio-rad-laboratories-inc-reports-material-event-84ad2c3fc6a1.html", "source_name": "Stock Titan", "published_at": "2026-04-30T20:39:34", "published_display": "30 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Huge Sartorius loss drives Bio-Rad (NYSE: BIO) Q1 2026 net loss", "summary": "Bio-Rad Laboratories reported a net loss of $527.1 million in Q1 2026, primarily due to a $738.2 million fair-value loss from equity securities and a loan receivable, including a significant $727.7 million holding loss on its investment in Sartorius AG. Despite this, net sales sl", "url": "https://www.stocktitan.net/sec-filings/BIO/10-q-bio-rad-laboratories-inc-quarterly-earnings-report-f49d8af29bd4.html", "source_name": "Stock Titan", "published_at": "2026-04-30T20:38:50", "published_display": "30 Apr 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad earnings on deck: Can margins recover after rough 2025?", "summary": "Bio-Rad Laboratories is set to report its first-quarter earnings, with investors keenly watching for signs of margin recovery after a challenging 2025 where performance fell below expectations. Analysts anticipate earnings of $2.01 per share on $591.28 million in revenue. Key fac", "url": "https://au.investing.com/news/earnings/biorad-earnings-on-deck-can-margins-recover-after-rough-2025-93CH-4397325", "source_name": "Investing.com Australia", "published_at": "2026-04-30T14:38:50", "published_display": "30 Apr 2026 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad will release Q1 results after market close on April 30", "summary": "Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced it will report its first-quarter 2026 financial results on Thursday, April 30, 2026, after the market closes. Management will host a conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) to discuss the results, w", "url": "https://www.stocktitan.net/news/BIO/bio-rad-to-report-first-quarter-2026-financial-results-on-thursday-r2s8rlzcf1pp.html", "source_name": "Stock Titan", "published_at": "2026-04-16T15:09:20", "published_display": "16 Apr 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard disaggregates holdings; Bio\u2011Rad Labs (NYSE: BIO) shows 0 shares", "summary": "The Vanguard Group filed an amended Schedule 13G/A for Bio-Rad Laboratories Inc. (NYSE: BIO), reporting beneficial ownership of 0 shares (0%) due to an internal realignment on January 12, 2026. This disaggregation of holdings means certain Vanguard subsidiaries will now report th", "url": "https://www.stocktitan.net/sec-filings/BIO/schedule-13g-a-bio-rad-laboratories-inc-amended-passive-investment-di-e516707415ee.html", "source_name": "Stock Titan", "published_at": "2026-03-26T20:38:51", "published_display": "26 Mar 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Disappointing Results Hurt Bio-Rad Laboratories (BIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNTFZxX09fWUR1Nk91TVUtb0MxSHJCNWpsREMzQnh4SkNEZHZDcHFhZXpocWZGQlUzLU96WWdRQ0Y4a1NjUzk3ckZiV1pfTkM1X0xlSE9jaU9JUk5vUEN2aXprVjJsMHEwM29hZFJmblg5RHNRMjJfU3BSRXBXczRPZkZzNTFSUmVZd3BKbndna2JuVzVTOVF4Q2htdE13ZU1B?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hound Partners LLC Has $29.15 Million Stake in Bio-Rad Laboratories, Inc. $BIO", "summary": "Hound Partners LLC significantly reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 42.9% in the third quarter, now holding 103,963 shares valued at $29.15 million. This represents about 3.7% of Hound's portfolio. Despite mixed analyst sentiment with a \"Hold\" rating an", "url": "https://www.marketbeat.com/instant-alerts/filing-hound-partners-llc-has-2915-million-stake-in-bio-rad-laboratories-inc-bio-2026-03-16/", "source_name": "MarketBeat", "published_at": "2026-03-17T07:10:14", "published_display": "17 Mar 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. $BIO Shares Purchased by Natixis Advisors LLC", "summary": "Natixis Advisors LLC significantly increased its stake in Bio-Rad Laboratories (NYSE:BIO) during Q3, purchasing an additional 26,119 shares, bringing their total to 65,069 shares valued at $18.25 million. This move is part of a broader trend of institutional investors modifying t", "url": "https://www.marketbeat.com/instant-alerts/filing-bio-rad-laboratories-inc-bio-shares-purchased-by-natixis-advisors-llc-2026-03-12/", "source_name": "MarketBeat", "published_at": "2026-03-12T18:53:00", "published_display": "12 Mar 2026 18:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capital Research Global Investors Makes New Investment in Bio-Rad Laboratories, Inc. $BIO", "summary": "Capital Research Global Investors has made a significant new investment in Bio-Rad Laboratories, purchasing 418,355 shares valued at approximately $117.3 million, representing about 1.55% ownership. This move comes as Bio-Rad reported Q4 EPS of $2.51, slightly missing estimates, ", "url": "https://www.marketbeat.com/instant-alerts/filing-capital-research-global-investors-makes-new-investment-in-bio-rad-laboratories-inc-bio-2026-03-12/", "source_name": "MarketBeat", "published_at": "2026-03-12T13:09:26", "published_display": "12 Mar 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10,425 Shares in Bio-Rad Laboratories, Inc. $BIO Purchased by Magnetar Financial LLC", "summary": "Magnetar Financial LLC recently acquired 10,425 shares of Bio-Rad Laboratories (NYSE:BIO) valued at approximately $2.923 million, contributing to institutional investors owning about 65.24% of the stock. Bio-Rad Laboratories reported mixed financial results, missing EPS estimates", "url": "https://www.marketbeat.com/instant-alerts/filing-10425-shares-in-bio-rad-laboratories-inc-bio-purchased-by-magnetar-financial-llc-2026-03-12/", "source_name": "MarketBeat", "published_at": "2026-03-12T10:52:26", "published_display": "12 Mar 2026 10:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Perbak Capital Partners LLP Purchases 5,423 Shares of Bio-Rad Laboratories, Inc. $BIO", "summary": "Perbak Capital Partners LLP significantly increased its stake in Bio-Rad Laboratories (NYSE: BIO) by 171.7% in the third quarter of 2026, acquiring 5,423 additional shares. The firm now holds 8,582 shares valued at $2.406 million, making it a substantial holding within their port", "url": "https://www.marketbeat.com/instant-alerts/filing-perbak-capital-partners-llp-purchases-5423-shares-of-bio-rad-laboratories-inc-bio-2026-03-14/", "source_name": "MarketBeat", "published_at": "2026-03-12T10:10:52", "published_display": "12 Mar 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Asset Management Inc Purchases 7,386 Shares of Bio-Rad Laboratories, Inc. $BIO", "summary": "TD Asset Management Inc. significantly increased its stake in Bio-Rad Laboratories (NYSE:BIO) by 461.0% in the third quarter, acquiring an additional 7,386 shares to hold a total of 8,988 shares valued at approximately $2.52 million. Despite this increased institutional interest,", "url": "https://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-purchases-7386-shares-of-bio-rad-laboratories-inc-bio-2026-03-05/", "source_name": "MarketBeat", "published_at": "2026-03-05T15:52:44", "published_display": "05 Mar 2026 15:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roubaix Capital LLC Buys Shares of 8,112 Bio-Rad Laboratories, Inc. $BIO", "summary": "Roubaix Capital LLC initiated a new position in Bio-Rad Laboratories (NYSE:BIO), acquiring 8,112 shares valued at approximately $2.275 million during the third quarter. The company reported slightly lower-than-expected quarterly earnings and revenue, with EPS of $2.51 against an ", "url": "https://www.marketbeat.com/instant-alerts/filing-roubaix-capital-llc-buys-shares-of-8112-bio-rad-laboratories-inc-bio-2026-03-03/", "source_name": "MarketBeat", "published_at": "2026-03-03T14:52:41", "published_display": "03 Mar 2026 14:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CenterBook Partners LP Has $2.56 Million Holdings in Bio-Rad Laboratories, Inc. $BIO", "summary": "CenterBook Partners LP reduced its stake in Bio-Rad Laboratories, Inc. by 36.4% in the third quarter, holding 9,129 shares valued at $2.56 million. Despite this, other institutions like Royal Bank of Canada and Goldman Sachs increased their positions, with institutional investors", "url": "https://www.marketbeat.com/instant-alerts/filing-centerbook-partners-lp-has-256-million-holdings-in-bio-rad-laboratories-inc-bio-2026-02-20/", "source_name": "MarketBeat", "published_at": "2026-02-24T16:52:53", "published_display": "24 Feb 2026 16:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sartorius 2025 results summarized in Bio-Rad (NYSE: BIO) update", "summary": "Bio-Rad Laboratories, Inc. (NYSE: BIO) has provided an update on its investment in Sartorius AG, sharing Sartorius's full-year 2025 financial figures which were disclosed on February 16, 2026. The update, filed as a Form 8-K, details Sartorius\u2019 sales revenue, gross profit, EBIT, ", "url": "https://www.stocktitan.net/sec-filings/BIO/8-k-bio-rad-laboratories-inc-reports-material-event-9de18110da65.html", "source_name": "Stock Titan", "published_at": "2026-02-23T13:52:01", "published_display": "23 Feb 2026 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(BIO) Movement Within Algorithmic Entry Frameworks", "summary": "This article provides an algorithmic analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details three trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014along with multi-timef", "url": "https://news.stocktradersdaily.com/news_release/21/BIO_Movement_Within_Algorithmic_Entry_Frameworks_022326123601_1771868161.html", "source_name": "Stock Traders Daily", "published_at": "2026-02-23T12:36:00", "published_display": "23 Feb 2026 12:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving Average - Time to Sell?", "summary": "Bio-Rad Laboratories (NYSE:BIO.B) shares have fallen below their 200-day moving average, trading at $261.83, which is below the $289.87 average, signaling a potential bearish technical trend. Despite this short-term weakness, the company's fundamentals remain strong, with robust ", "url": "https://www.marketbeat.com/instant-alerts/bio-rad-laboratories-nysebiob-shares-pass-below-200-day-moving-average-time-to-sell-2026-02-21/", "source_name": "MarketBeat", "published_at": "2026-02-21T12:51:52", "published_display": "21 Feb 2026 12:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics", "summary": "Bio-Rad Laboratories (BIO) recently informed investors about selected 2025 financial metrics from its strategic investment in Sartorius AG. Sartorius reported \u20ac3.54 billion in sales revenue and \u20ac542.6 million in EBIT for 2025, providing transparency on the financial health of thi", "url": "https://www.tipranks.com/news/company-announcements/bio-rad-updates-investors-on-sartorius-strategic-investment-metrics", "source_name": "TipRanks", "published_at": "2026-02-20T18:51:32", "published_display": "20 Feb 2026 18:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio Rad Laboratories Q3 Loss Of US$12.70 EPS Tests Recovery Narrative For BIO Stock", "summary": "Bio-Rad Laboratories (BIO) reported a Q3 FY 2025 basic EPS loss of US$12.70 and US$653 million in revenue, presenting a mixed picture against its volatile financial history. The company's trailing 12-month net loss is US$675.9 million, with analysts forecasting a return to profit", "url": "https://www.sahmcapital.com/news/content/bio-rad-laboratories-q3-loss-of-us1270-eps-tests-recovery-narrative-for-bio-stock-2026-02-14", "source_name": "Sahm", "published_at": "2026-02-16T13:52:01", "published_display": "16 Feb 2026 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPSTYxMFhyN2MtOVEyWWdSd1NjYzk5bHFxclJNVmlCLUdpektDWDE5THNmM3hXRXI3cDZ0bXhCZ3l5TnczbGNuSjhSdkx5cTV6ZE1oQlBsa01LLVJycS1feGIyUmxQRHNwV1gtLU9WMngwRjZRTURBRXE1YnJ4ZGtXZkRIZms3SXM?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories (NYSE:BIO.B) Posts Quarterly Earnings Results", "summary": "Bio-Rad Laboratories (NYSE:BIO.B) recently announced its quarterly earnings, reporting $2.51 EPS. Despite a negative net margin of 26.43%, the company achieved a positive return on equity of 4.19%. Shares remained flat at $295.05 on minimal trading volume, indicating strong liqui", "url": "https://www.marketbeat.com/instant-alerts/bio-rad-laboratories-nysebiob-posts-quarterly-earnings-results-2026-02-12/", "source_name": "MarketBeat", "published_at": "2026-02-13T00:27:54", "published_display": "13 Feb 2026 00:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQQ0stWDJjdVBBNHFUcWFFSkw2S0FfV0IzWXRtalJ4N192a0RvQl9UOUlVSjJrQTRQUWNZUUc4bXdMX0VxSUJ1TDUyakhEMFpUOFNHaTNPbUVGblhDVl9pYzktQlZyMi0yYURYa1JsdGZzREQ5YXdOWE1HZEhYLTBlYw?oc=5", "source_name": "Market source", "published_at": "2025-03-07T08:00:00+00:00", "published_display": "07 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bio-Rad Laboratories: This Undervalued Stock Offers Investors a Rare Combination", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxORVczUEktaG9PZ1dkMjMxWTk1TDZlUVFCX0dvbFZ6eEJTd2VXVmlFZWZZNXI0WUJ0UUFtMm4xanpSOTc0YS1VRHhBLUJ5dlBTRUxQMTNiTEkwQ2gwS1NnU3VwX1EyUVFEdVFTMmxBd0I0bDdkYTFLMTUxQzdxSFJOeG9VbXhMQTJqdmZrZ3dDN3ROMTJTaWc?oc=5", "source_name": "Morningstar", "published_at": "2024-11-11T08:00:00+00:00", "published_display": "11 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 107, "total_relevant": 50, "sentiment_summary": {"positive": 2, "negative": 2, "neutral": 46, "score": 50, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 79, "events": [{"event": "earnings", "label": "Earnings", "weight": 14.16, "count": 28}, {"event": "general", "label": "Market update", "weight": 8.6, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 2, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 298.5, "latest_week": "2026-07-10", "one_week_move": 0.7, "four_week_move": -1.9, "twelve_week_move": 7.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.715036, "market_dynamics_buy_signal": false, "relative_strength": -5.673243, "fair_value_gap": -1.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 19.8914, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.7% over one week, -1.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 48, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "MarketBeat", "count": 11}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 4}, {"label": "Ad Hoc News", "count": 3}, {"label": "StockStory", "count": 3}, {"label": "TradingView", "count": 1}, {"label": "Finviz", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 28}, {"label": "Market update", "count": 15}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.7% over one week, -1.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings"}], "updated_at": "2026-07-18T00:32:21.994087+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}